223: Fauci's non-retirement, grading biotech VCs, & a bellwether IPO
Our colleague Helen Branswell joins to explain the Covid-19 booster debate, the Biden Administration’s monkeypox response, and the long career of the soon-to-step-down Anthony Fauci. We also discuss t...
25 Aug 202230min
222: Private equity in autism care, a watershed FDA approval, & the future of ALS treatment
First, STAT's Tara Bannow joins us to discuss how private equity's mounting interest in autism care has created an untenable situation for many parents in the U.S. We also explain the implications of ...
18 Aug 202229min
221: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing
Are biotech's fortunes finally changing? Is Big Science impeding actual science? And what will Medicare negotiation mean for drug prices? STAT's Jason Mast joins us to discuss Jim Wilson, a pioneering...
11 Aug 202229min
220: The last-minute push for drug pricing reform, Alnylam's success, and Sarepta's gamble
Is drug pricing reform really happening this time? Are things finally turning around for biotech? And is it ever wise to tweet your food? Rachel Cohrs, STAT's Washington correspondent, joins us to exp...
4 Aug 202233min
219: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer's data
Can monkeypox be contained? Are snortable Covid-19 vaccines on the way? And when is a GIF worth $200,000? STAT's Helen Branswell joins us to explain the latest in the monkeypox outbreak and how health...
28 Jul 202235min
218: Well-paid CEOs, behind the scenes at Moderna, & Biogen's CEO search
Does any CEO deserve $500 million a year? How did Moderna hit it big? And who wants to run Biogen? STAT's Bob Herman joins us to explain why health care CEOs get paid so much — and why company-reporte...
21 Jul 202238min
217: CRISPR for the heart, biotech's recovery, & what it means to be a 'hot girl'
Can CRISPR edit out a heart attack? What happens on #GutTok? And is health care recession-proof? Sek Kathiresan, cardiologist and CEO of Verve Therapeutics, joins us to explain the company's work on p...
14 Jul 202230min
216: VC malaise, FDA confusion, & yet another Alzheimer's debate
Is the era of the unicorn over? What's gotten into the FDA? And will a NASH drug ever work? Our colleague Allison DeAngelis joins us to explain how the prolonged downturn for biotech stocks is stoking...
7 Jul 202228min
